Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuradiab in Newly Diagnosed Glioblastoma Multiforme
NCT00615186Phase 3Terminated
- Sponsor
- Bradmer Pharmaceuticals Inc.
- Start
- Jun 2008
- Primary completion
- Aug 2013
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of iodine i 131 monoclonal antibody 81c6 in glioblastoma multiforme (GBM), sponsored by Bradmer Pharmaceuticals Inc.. Started Jun 2008; status: terminated.
02
Drugs
iodine i 131 monoclonal antibody 81c6
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00615186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00615186.